Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation

The effect of the oral selective vasopressin V2-receptor antagonist tolvaptan for chronic phase therapy on patients with FMR remains unclear. We aimed to determine the efficacy of oral tolvaptan in patients with significant functional mitral regurgitation (FMR) to reduce the mortality and rehospital...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Heart and vessels 2022-03, Vol.37 (3), p.434-442
Hauptverfasser:	Nagura, Fukuko, Kataoka, Akihisa, Ishibashi, Ruri, Mitsui, Miho, Hioki, Hirofumi, Kuwabara, Masanari, Uno, Kiyoko, Watanabe, Yusuke, Yokoyama, Naoyuki, Kozuma, Ken
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical Engineering and Bioengineering Cardiac Surgery Cardiology Congestive heart failure Diuretics Medicine Medicine & Public Health Mortality Original Article Patients Regurgitation Vascular Surgery Vasopressin Weighting methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!